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Abstract 
Objective: The aim of the present study was to evaluate the prognostic value of the Stanniocalcin‑2/PAPP‑A/IGFBP‑4 
axis in patients with ST‑segment elevation myocardial infarction (STEMI).
Methods: Observational cohort study performed in 1085 consecutive STEMI patients treated with early reperfusion 
between February 2011 and August 2014. Stanniocalcin‑2, PAPP‑A, and IGFBP‑4 were measured using state‑of‑the 
art immunoassays. The primary outcome was the composite endpoint of all‑cause mortality and readmission due to 
heart failure (HF).
Results: Median follow‑up was 3.3 years (IQR 1.0–3.7), during which 176 patients (16.2%) presented a composite 
endpoint. Multivariable cox regression analysis revealed that Stanniocalcin‑2 (HR 2.06; 95% CI 1.13–3.75; p = 0.018), 
IGFBP‑4 (HR 1.73; 95% CI 1.14–2.64; p = 0.010), Killip–Kimball class III–IV (HR 1.40; 95% CI 1.13–1.74; p = 0.002), NT‑
ProBNP (HR 1.21; 95% CI 1.07–1.37; p = 0.002), age (HR 1.06; 95% CI 1.04–1.08; p < 0.001) and left ventricular ejection 
fraction (HR 0.97; 95% CI 0.95–0.98; p < 0.001) were independent predictors of the composite endpoint. A model 
containing Stanniocalcin‑2 and IGFBP‑4 on top of clinical variables significantly improved C‑index discrimination 
(p = 0.036). Stanniocalcin‑2 was also identified as independent predictor of all‑cause mortality (HR 2.23; 95% CI 
1.16–4.29; p = 0.017) and readmission due to HF (HR 3.42; 95% CI 1.22–9.60; p = 0.020).
Conclusions: In STEMI patients, Stanniocalcin‑2 and IGFBP‑4 emerged as independent predictors of all‑cause 
death and readmission due to HF. The Stanniocalcin‑2/PAPP‑A/IGFBP‑4 axis exhibits a significant role in STEMI risk 
stratification.
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Background
Patients with acute ST-segment elevation myocardial 
infarction (STEMI) are at considerable risk for car-
diovascular complications and death despite remark-
able advances in non-invasive and invasive treatment 
[1]. Early risk stratification is therefore important for 
the assessment of prognosis as well as to guide adequate 
secondary prevention treatment. In this setting, the value 
of biomarkers reflecting different disease pathways is 
under scrutiny.
Pregnancy-associated plasma protein-A (PAPP-A), 
a high molecular weight and zinc-binding metallopro-
teinase, has been regarded a candidate marker in cardi-
ovascular disease and vulnerable plaque [2, 3]. PAPP-A 
is an important regulatory protein in cell proliferation 
and the development of atherosclerosis [4, 5, 9]. PAPP-
A is specific for three insulin-like growth factor binding 
proteins (IGFBP-2, -4, and -5) and functions intimately 
with IGFBP-4, which is a key regulator of insulin-like 
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growth factor (IGF) bioactivity [6–8]. Recently, Stan-
niocalcin-2 was identified as a novel modulator of IGF 
bioavailability due to its potential to inhibit the proteo-
lytic activity of PAPP-A [9] (Fig.  1). In atherosclerotic 
plaques, PAPP-A and Stanniocalcin-2 are abundantly 
expressed [10]. Collectively, the Stanniocalcin-2/PAPP-
A/IGFBP-4 axis regulates local IGF bioavailability and 
signaling with potential biological implications in car-
diovascular disease [8]. Despite recent studies showing 
that PAPP-A and IGFBP-4 are potentially important 
biomarkers for the prediction of adverse outcomes in 
patients with acute coronary syndrome [11, 12], the 
evidence is scarce in contemporary-treated STEMI 
patients promptly reperfused, and to date, there are no 
reports on the prognostic value of Stanniocalcin-2 in 
this population.
Accordingly, the present study was designed to evalu-
ate the prognostic value of the Stanniocalcin-2/PAPP-A/
IGFBP-4 axis in a consecutive STEMI population exclu-
sively treated by primary percutaneous coronary inter-
vention (PPCI).
Methods
Study design and population
Prospective observational study that included con-
secutive STEMI patients treated with PPCI between 
February 22, 2011, and November 11, 2014. Our insti-
tute is a tertiary university hospital that serves a popu-
lation of ~ 850,000 inhabitants, mainly distributed 
among 4 urban areas located 2, 7, 20, or 45 km from our 
PPCI-capable unit. The diagnosis of STEMI was estab-
lished when patients presented with chest pain and an 
Fig. 1 Schematic of the Stanniocalcin‑2/PAPP‑A/IGFBP‑4 axis. Left: Stanniocalcin‑2 inhibits PAPP‑A cleavage of IGFBP‑4 thereby resulting in 
decreased levels of free IGF, and consequently decreased IGF signaling. Right: in the absence of Stanniocalcin‑2, PAPP‑A cleaves IGFBP‑4, resulting 
in liberation of free IGF. Because free IGF can bind its receptor, IGF signaling is then induced. STC-2 Stanniocalcin‑2, PAPP-A pregnancy‑associated 
plasma protein‑A, IGFBP-4 insulin‑like growth factor binding protein 4, IGF insulin‑like growth factor
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electrocardiogram showed ST-segment elevation in two 
or more contiguous leads (elevation was defined as a 
minimum of 0.1 mV in the frontal leads and 0.2 mV in the 
precordial leads) or with a left bundle branch block (new 
onset or indeterminate chronology) that evolved within 
6 h [13, 14]. Baseline demographics and clinical data were 
recorded during hospital admission. Blood samples were 
obtained upon coronary angiography and were processed 
in a central laboratory for biomarker measurements. The 
left ventricular ejection fraction (LVEF) was assessed 
within the first 24 h of admission with echocardiography 
(Agilent Sonos 5500-Philips and ie33-Philips) using the 
Simpson method.
Study outcome and follow‑up
The main clinical outcome was the composite of all-cause 
mortality and readmission due to heart failure (HF). Fol-
low-up events were obtained from searching the patients’ 
electronic clinical records, death registers or by contact-
ing the patient’s relatives. For patients with recurrent 
events, the time to the first event was recorded. All par-
ticipants gave their informed consent, and this study was 
performed in compliance with the Helsinki Declaration, 
and was approved by the local Ethics Committee.
Biomarker assays
High sensitive troponin T (hs-TnT) was measured with 
an electrochemiluminescence immunoassay (ultrasensi-
tive troponin T method, ref 05092744 190; Roche Diag-
nostics) performed on a cobas e601 analyzer (Roche 
Diagnostics). The analytic performance of this assay has 
been validated [15]. As described by the manufacturer 
(ref 05092744 190; Roche Diagnostics), the 99th percen-
tile for normal was 14 ng/L and the functional sensitivity 
(limit of quantification with a coefficient of variation of 
< 10%) was 13 ng/L. NT-proBNP levels were determined 
using an immuno-electrochemiluminescence assay and 
the Modular Analytics E170 (Roche Diagnostics Inc., 
Indianapolis, IN). This assay has < 0.001% cross-reac-
tivity with bioactive BNP, and the assay had inter-run 
coefficients of variation ranging from 0.9 to 5.5%. Immu-
noassays for Stanniocalcin-2, PAPP-A, and intact 
IGFBP-4 were from AnshLabs, Webster, TX, USA. Stan-
niocalcin-2 levels were measured using an enzyme linked 
immunosorbent assay (AL-143) with a limit of detection 
of 0.033 ng/mL; PAPP-A was measured with an enzyme 
linked immunosorbent assay (picoPAPP-A, AL-101), 
and as described by the manufacturer the limit of detec-
tion is 0.037 ng/mL; intact IGFBP-4 was measured with 
an enzyme linked immunosorbent assay (AL-124) with a 
limit of detection of 0.669 ng/mL.
Statistical analysis
Categorical variables are presented as number and per-
centage. Continuous variables are reported as median 
and interquartile range. Non-normally distributed vari-
ables were log-transformed prior to statistical analyses. 
A composite endpoint including all events was used for 
comparison of baseline characteristics. Patients with or 
without events during follow-up were compared using 
the Chi squared test or Fisher’s exact test for categorical 
variables and the Wilcoxon rank sum test for continu-
ous variables. Survival analyses were performed using 
Cox proportional hazards models (using the backward 
elimination method). Hazard ratios (HRs) with 95% 
confidence intervals (CIs) are reported. The following 
variables were incorporated into the regression models: 
age, sex, history of hypertension, diabetes mellitus, cer-
ebrovascular disease, HF, myocardial infarction, previous 
coronary artery disease, Killip–Kimball class category, 
LVEF, estimated glomerular filtration rate, low-density 
lipoprotein, PAPP-A, Stanniocalcin-2, IGFBP-4, hs-TnT 
and NT-ProBNP. For each end-point, the interactions 
between the Stanniocalcin-2, PAPP-A and IGFBP-4 was 
explored without finding statistically significance in any 
of them. To evaluate the proportional hazards assump-
tion, Schoenfeld residuals were assessed. We used a mul-
tivariable competing risk model to obtain the HRs for 
readmission due to HF, considering death as a competing 
event. We plotted log-derived hazards for major cardio-
vascular events relative to baseline Stanniocalcin-2 and 
IGFBP-4 values using fractional polynomials. To assess 
the discrimination benefit of adding PAPP-A, IGFBP-4 
and Stanniocalcin-2 to a clinical model, Harrell’s C statis-
tics was used; calibration was assessed using the Royston 
modification of Nagelkerke’s R2 statistic for proportional 
hazards models, and continuous net reclassification 
improvement (NRI) was used for reclassification pre-
diction. Statistical analysis was performed using STATA 
V.13.0 (College Station, Texas, USA). A p value of < 0.05 
was considered significant.
Results
Baseline characteristics
From a total of 1163 consecutive patients admitted dur-
ing the study period, 1085 (93.3%) had all biomarkers 
measured and were finally included in the study. Median 
follow-up was 3.3 years (IQR 1.0–3.7), during which 176 
patients (16.2%) presented a composite endpoint (136 
deaths and 60 readmissions due to HF). Table 1 shows the 
baseline characteristics of patients included in the study. 
Patients with events were more likely to be women and 
older and were more likely to have a history of arterial 
hypertension, diabetes mellitus, cerebrovascular disease, 
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peripheral arterial disease, HF and myocardial infarction. 
Patients who presented the composite endpoint exhib-
ited greater disease severity (Killip–Kimball class III or 
IV, 25.0% vs. 3.5%; p < 0.001) worse LVEF (45% vs. 54%; 
p < 0.001) and more prevalent extensive coronary artery 
disease (3-vessel disease) than patients without events 
during follow-up (32.4% vs. 17.1%; p < 0.001).
An unadjusted analysis showed that patients with 
events had a significantly higher median (IQR) hs-TnT 
levels (4375 [1357–91,485] vs. 2643 [934–5590]  ng/L; 
p < 0.001) and higher median NT-ProBNP levels (3461 
[1569–7396] vs. 827 [356–1707]  ng/L; p < 0.001). Like-
wise, median levels of PAPP-A (12.3 [5.4–28.6] vs. 
10.1 [4.2–22.5]  µg/L; p = 0.019), Stanniocalcin-2 (19.2 
[15.3–24.3] vs. 17.5 [14.7–21.2]  µg/L; p < 0.001) and 
intact (uncleaved) IGFBP-4 (36.8 [27.6–48.1] vs. 29.5 
[23.0–36.7] µg/L; p < 0.001) were also significantly higher 
in patients who presented the composite endpoint com-
pared with those without events.
Predictors of long‑term outcomes
Multivariable Cox proportional-hazard regression mod-
els showed that Stanniocalcin-2 (HR 2.06; 95% CI 1.13–
3.75; p = 0.018), IGFBP-4 (HR 1.73; 95% CI 1.14–2.64; 
p = 0.010), Killip–Kimball class III or IV (HR 1.40; 95% 
CI 1.13–1.74; p = 0.002), NT-ProBNP (HR 1.21; 95% 
CI 1.07–1.37; p = 0.002), age (HR 1.06; 95% CI 1.04–
1.08; p < 0.001) and LVEF (HR 0.97; 95% CI 0.95–0.98; 
p < 0.001) were independent predictors of the composite 
endpoint during follow-up. Further, Stanniocalcin-2 was 
identified as independent predictor of all-cause mortal-
ity (HR 2.23; 95% CI 1.16–4.29; p = 0.017) and readmis-
sion due to HF (HR 3.42; 95% CI 1.22–9.60; p = 0.020) 
(Table  2). There was no significant association between 
PAPP-A or hs-TnT levels and the composite endpoint 
(Table 3). The relationship between Stanniocalcin-2 and 
IGFBP-4 levels as continuous variables and the relative 
risk for the composite endpoints is shown in Fig. 2.
Table 4 shows calibration, discrimination and reclassi-
fication metrics to evaluate the incremental value of the 
Stanniocalcin-2/PAPP-A/IGFBP-4 axis components over 
a clinical model for prediction of events during follow-
up. For the composite endpoint, the addition of each bio-
marker alone to the clinical model did not significantly 
improve discrimination; however, a model containing 
Stanniocalcin-2 and IGFBP-4 on top of clinical variables 
improved discrimination, with an increase in the C-index 
from 0.815 to 0.826 (p = 0.036) with a higher Nagelkerke’s 
Table 1 Baseline characteristics of the studied cohort relative to the presence of events
Data represent the number (%) or median (interquartile range). Wilcoxon Rank-sum test was used for comparisons of continuous variables
PCI percutaneous coronary intervention, BMI body mass index, hs-TnT high-sensitivity troponin T, LVEF left ventricular ejection fraction
Variable All patients
(n = 1085)
Without events
(n = 909)
With events
(n = 176)
p value
Age (years) 62 (52–73) 59 (51–69) 76 (66–81) < 0.001
Female 241 (22.2) 187 (20.6) 54 (30.7) 0.003
Hypertension 598 (55.1) 473 (52.0) 125 (71.0) 0.001
Diabetes mellitus 276 (25.4) 208 (22.9) 68 (38.6) < 0.001
Dyslipidemia 645 (59.5) 550 (60.5) 95 (54.0) 0.106
Cerebrovascular disease 69 (6.4) 42 (4.6) 27 (15.3) < 0.001
Peripheral arterial disease 77 (7.1) 57 (6.3) 20 (11.4) 0.016
Heart failure 18 (1.7) 7 (0.8) 11 (6.3) < 0.001
Coronary artery disease 236 (21.8) 188 (20.7) 48 (27.3) 0.052
Myocardial infarction 103 (9.5) 76 (8.4) 27 (15.3) 0.004
Killip–Kimball I–II 1009 (93.0) 877 (96.5) 132 (75.0) < 0.001
Killip–Kimball III–IV 76 (7.0) 32 (3.5) 44 (25.0) < 0.001
BMI (kg/m2) 27.3 (24.8–29.9) 27.2 (24.8–29.8) 27.6 (24.3–30.0) 0.944
Hs‑TnT, peak (ng/L) 2752 (1021–6057) 2643 (934–5590) 4375 (1357–91,485) < 0.001
NT‑ProBNP, peak (ng/L) 1003 (395–2421) 827 (356–1707) 3461 (1569–7396) < 0.001
LVEF (%) 52 (45–58) 54 (47–59) 45 (38–53) < 0.001
Main epicardial coronary arteries > 70% stenosis
 1 564 (52.0) 493 (54.2) 71 (40.3) 0.001
 2 287 (26.5) 253 (27.8) 34 (19.3) 0.019
 3 212 (19.5) 155 (17.1) 57 (32.4) < 0.001
Left main ≥ 50% stenosis 40 (3.7) 25 (2.8) 15 (8.5) < 0.001
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R2. The associated continuous NRI was 0.140 95% CI 
[0.004–0.428], corresponding to 6.2% patients reclassi-
fied. For the prediction of all-cause mortality or HF read-
mission, the addition of these biomarkers to the clinical 
model did not significantly improve performance metrics 
(Table 4).
Discussion
Main findings
This observational prospective study investigated the 
association between the Stanniocalcin-2/PAPP-A/
IGFBP-4 axis and adverse events in a cohort of unse-
lected patients with STEMI. After adjusting for clinical 
predictors, Stanniocalcin-2 and IGFBP-4 were significant 
and independent predictors of the composite endpoint 
and Stanniocalcin-2 emerged also as an independent pre-
dictor of all-cause mortality and readmission due to HF. 
These findings suggest that the Stanniocalcin-2/PAPP-
A/IGFBP-4 axis is of value in the risk stratification of 
STEMI patients.
Stanniocalcin‑2/PAPP‑A/IGFBP‑4 axis and long‑term 
outcomes
PAPP-A is a large, zinc binding proteinase produced 
by different cell types, including fibroblasts, vascular 
smooth muscle cells, and male and female reproduc-
tive tissues, and is widely used in prenatal screening 
[16]. PAPP-A shows proteolytic activity towards IGFBP-
2, IGFBP-4 and IGFBP-5. It functions intimately with 
IGFBP-4 and its cleavage that occurs in close proximity 
Table 2 Multivariable Cox regression analyses 
for the composite endpoint of all-cause mortality 
and readmission due to heart failure
IGFBP-4 insulin-like growth factor binding protein-4, LVEF left ventricular ejection 
fraction
a HRs (95% CIs) are reported per 1-SD increment of natural log-transformed 
plasma levels
HR (95% CI) p value
Composite endpoint
 Stanniocalcin‑2a 2.06 (1.13–3.75) 0.018
 IGFBP‑4a 1.73 (1.14–2.64) 0.010
 Killip–Kimball class III–IV 1.40 (1.13–1.74) 0.002
 NT‑ProBNPa 1.21 (1.07–1.37) 0.002
 Age 1.06 (1.04–1.08) < 0.001
 LVEF 0.97 (0.95–0.98) < 0.001
All‑cause mortality
 Stanniocalcin‑2a 2.23 (1.16–4.29) 0.017
 Killip–Kimball class II–IV 1.64 (1.30–2.08) < 0.001
 NT‑ProBNPa 1.18 (1.02–1.36) 0.028
 Age 1.07 (1.05–1.10) < 0.001
 LVEF 0.97 (0.95–0.99) 0.002
Readmission due to heart failure
 Stanniocalcin‑2a 3.42 (1.22–9.60) 0.020
 Prior myocardial infarction 2.85 (1.32–6.16) 0.008
 Diabetes mellitus 2.36 (1.22–4.58) 0.011
 Female sex 2.21 (1.15–4.28) 0.018
 Age 1.04 (1.01–1.07) 0.005
 LVEF 0.94 (0.92–0.97) < 0.001
Table 3 Univariable and multivariable Cox regression analyses for the composite endpoint of all-cause mortality 
and readmission due to heart failure
All HRs (95% CIs) are reported per 1-SD increment of natural log-transformed plasma levels
hs-TnT high-sensitivity troponin T, PAPP-A pregnancy-associated plasma protein-A, IGFBP-4 insulin-like growth factor binding protein-4
Composite endpoint All‑cause mortality Readmission due to HF
HR (95% CI) p HR (95% CI) p HR (95% CI) p
PAPP‑A
 Univariable 1.25 (1.09–1.42) 0.001 1.30 (1.12–1.51) 0.001 1.08 (0.85–1.38) 0.525
 Adjusted 1.13 (0.94–1.35) 0.185 1.10 (0.90–1.35) 0.340 0.94 (0.65–1.35) 0.729
Stanniocalcin‑2
 Univariable 2.90 (1.81–4.64) < 0.001 2.52 (1.47–4.29) 0.001 5.37 (2.35–12.26) < 0.001
 Adjusted 2.06 (1.13–3.75) 0.018 2.23 (1.16–4.29) 0.017 3.42 (1.22–9.60) 0.020
IGFBP‑4
 Univariable 3.29 (2.47–4.39) < 0.001 3.18 (2.30–4.39) < 0.001 2.69 (1.83–3.97) < 0.001
 Adjusted 1.73 (1.14–2.64) 0.010 1.44 (0.85–2.44) 0.170 0.82 (0.42–1.60) 0.562
Hs‑TnT
 Univariable 1.48 (1.32–1.65) < 0.001 1.44 (1.27–1.63) < 0.001 1.64 (1.36–1.98) < 0.001
 Adjusted 1.07 (0.91–1.25) 0.424 1.04 (0.87–1.25) 0.665 1.00 (0.81–1.26) 0.959
NT‑ProBNP
 Univariable 1.69 (1.54–1.84) < 0.001 1.66 (1.50–1.84) < 0.001 1.68 (1.43–1.97) < 0.001
 Adjusted 1.21 (1.07–1.37) 0.002 1.18 (1.02–1.36) 0.028 1.24 (0.92–1.68) 0.157
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to the IGF1 receptor allows dissociation of bound active 
IGF, increasing IGF signaling through receptor stimula-
tion [17]. Recently, Stanniocalcin-2 has been reported to 
be a potent inhibitor of PAPP-A proteolytic activity. Stan-
niocalcin-2 binds covalently to PAPP-A to completely 
eliminate its activity toward IGFBP-4 and hence PAPP-
A-mediated IGF signaling [9]. Thus, the Stanniocalcin-2/
PAPP-A/IGFBP-4 axis regulates local IGF bioavail-
ability and signaling (Fig.  1) stimulating cell prolifera-
tion and promoting macrophage activation, low-density 
lipoprotein uptake and release of pro-inflammatory 
cytokines [18]. This axis represents an intriguing disease 
pathway of increasing interest.
The first component of the axis that was related to 
atherosclerosis was PAPP-A. In 2001, Bayes-Genis 
et al. [2] first described that circulating PAPP-A levels 
are upregulated in acute coronary syndrome (ACS), 
suggesting that PAPP-A might be a useful biomarker 
of plaque instability, Since then, several studies have 
shown that elevations of PAPP-A are associated with 
Fig. 2 Multivariable analyses for MACE. a HR gradient (shaded area = 95% CI), with median Stanniocalcin‑2 value (17.8 µg/L) as reference. b 
HR gradient (shaded area = 95% CI), with median IGFBP‑4 value (30.5 µg/L) as reference. Both analyses adjusted for age, sex, history of arterial 
hypertension, diabetes mellitus, heart failure, myocardial infarction, glomerular filtration rate, killip–kimball class and left ventricular ejection fraction. 
CI confidence interval, HR hazard ratio, MACE major adverse cardiovascular events
Table 4 Performance of Models for the composite endpoint of all-cause mortality and readmission due to heart failure
Clinical model includes: age, sex, history of arterial hypertension, diabetes mellitus, heart failure, myocardial infarction, glomerular filtration rate and left ventricular 
ejection fraction
IGFBP-4 insulin-like growth factor binding protein-4
Marker C‑statistic (p value) Nagelkerke’s  R2 cNRI Reclassification
Composite endpoint
 Clinical model (CM) 0.815 0.645
  CM + Stanniocalcin‑2 0.821 (p = 0.100) 0.660 0.125 (− 0.053–0.363) 3.8% (0.9–6.9%)
  CM + IGFBP‑4 0.823 (p = 0.113) 0.671 0.270 (0.064–0.431) 5.0% (2.2–8.9%)
  CM + Stanniocalcin‑2 + IGFBP‑4 0.826 (p = 0.036) 0.677 0.176 (0.001–0.420) 6.2% (3.1–9.6%)
All‑cause mortality
 Clinical model (CM) 0.807 0.636
  CM + Stanniocalcin‑2 0.808 (p = 0.555) 0.646 0.129 (− 0.129–0.330) 2.4% (0.3–4.8%)
  CM + IGFBP‑4 0.814 (p = 0.241) 0.662 0.248 (0.001–0.412) 3.7% (1.2–6.6%)
  CM + Stanniocalcin‑2 + IGFBP‑4 0.814 (p = 0.204) 0.664 0.185 (− 0.041–0.433) 4.1% (1.6–7.0%)
Readmission due to heart failure
 Clinical model (CM) 0.861 0.802
  CM + Stanniocalcin‑2 0.872 (p = 0.211) 0.825 0.256 (− 0.129–0.653) 1.31% (0.2–3.0%)
  CM + IGFBP‑4 0.861 (p = 0.103) 0.806 0.114 (− 0.285–0.446) 0.4% (0.0–1.9%)
  CM + Stanniocalcin‑2 + IGFBP‑4 0.869 (p = 0.413) 0.823 0.239 (− 0.148–0.611) 1.6% (0.3–3.1%)
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recurrent cardiovascular events in patients with non-
ST segment elevation-ACS [19, 20] and in patients with 
stable cardiovascular disease and indications for car-
diac catheterization [21] Subsequent studies showed 
that heparin treatment, common among ACS patients, 
induces a drastic increase in serum PAPP-A within few 
minutes, from the arterial wall and not atherosclerotic 
plaques, shedding doubt on PAPP-A as a reliable bio-
marker of adverse events in ACS [22–24]. In this study, 
PAPP-A was measured immediately before catheteriza-
tion but after heparin administration.
Consequently, different assays that measure IGFBP-4 as 
the cleaved substrate of active PAPP-A have been devel-
oped, on the basis that it may be reflective of PAPP-A 
enzymatic activity and may reflect plaque burden serv-
ing as marker of atherosclerosis [25]. Studies of IGFBP-4 
as a cardiac risk marker have shown controversial results 
that may be justified by the differences in the study pop-
ulation, and the clinical setting where the IGFBP-4 was 
studied. In patients with stable cardiovascular disease, 
Schulz et  al. [26] found that CT- and NT-IGFBP4 lev-
els failed to predict any long-term outcomes, whereas 
Postnikov et  al. [25] found that in patients with symp-
toms of myocardial ischemia but without ST-segment 
elevation, both NT- and CT-IGFBP-4 were strong predic-
tors of major adverse cardiac events and more recently, 
Hjortebjerg et  al. [12] found that IGFBP-4 fragments 
were associated with increased risk of all-cause mortal-
ity, cardiovascular mortality and major adverse cardiac 
events in patients with STEMI. Nonetheless, our results 
support the evidence that in STEMI patients, IGFBP-4 is 
associated with an increased risk of adverse events dur-
ing long term follow-up and favor the hypothesis that its 
prognostic ability is notable in patients in the acute phase 
of a myocardial infarction, even in the contemporary 
setting of routine primary PCI. The prognostic value of 
intact IGFBP-4 shown in our study, differs from what was 
previously observed by Postnikov [25] and Hjortebjerg 
[12], where measurements of full-length IGFBP4 were 
not predictive for MACE and intact IGFBP-4 did not per-
form better than C reactive protein or peak troponin I 
for any end point, respectively. These differences may in 
part be explained by the different immunoassays used in 
the studies. Further, previous in vitro and in vivo studies 
have shown that intact IGFBP-4 exerts mainly inhibitory 
effects on IGF functionality [27]. Thus, we hypothesized 
that in the setting of ACS, the increased PAPP-A proteo-
lytic activity with secondary augmented IGF bioavailabil-
ity leads to increased serum levels of intact IGFBP-4 as a 
regulatory response; this is likely the reason higher levels 
of intact IGFBP-4 are associated with the composite end-
point in this clinical setting.
Due to the recent discovery of Stanniocalcin-2 as a 
novel proteinase inhibitor of PAPP-A, we considered 
that it could also reflect PAPP-A enzymatic activity, with 
potential prognostic implications in the setting of acute 
coronary syndrome similarly to IGFBP-4. In this study 
we found that elevated levels of Stanniocalcin-2 are sig-
nificantly associated with increased risk of all-cause 
mortality and readmission due to HF in STEMI patients. 
We hypothesized that Stanniocalcin-2 levels are regu-
lated by IGF bioavailability: in a high PAPP-A setting 
with subsequent cleavage of the IGFBP-4/IGF1 complex 
and increased IGF signaling (e.g. in ACS where PAPP-
A is abundantly expressed in both eroded and ruptured 
plaques), higher levels of Stanniocalcin-2 arise as a com-
pensatory response. It should be emphasized that Stan-
niocalcin-2 upregulation unrelated to IGF signaling is 
also possible; this upregulation might be also activated 
in response to oxidative stress and hypoxia after coro-
nary artery occlusion in a similar way to what had been 
demonstrated in the animal model after cerebral artery 
occlusion [28] or in the setting of hypoxic tumor micro-
environment [29].
At the turn of the century, some studies suggested 
that low IGF-I levels were associated with increased 
ischemic heart disease [30] and that IGF-1 protects 
against endothelial dysfunction, atherosclerotic plaque 
development, metabolic syndrome, clinical instabil-
ity, and ischemic myocardial damage [31]. By contrast, 
more recent research in preclinical models showed that 
smooth muscle cell proliferation and migration in neoin-
timal hyperplasia was markedly reduced in the absence of 
PAPP-A [32] and that PAPP-A substrate binding site inhi-
bition reduces atherosclerotic plaque burden [33]; sup-
porting this theory, and specifically in the population of 
STEMI patients, our results suggest that within the axis, 
elevated levels of Stanniocalcin-2 and intact IGFBP-4 can 
be interpreted as a regulatory response to high PAPP-A 
proteolytic activity, The specific mechanisms in STEMI 
patients warrant further investigation.
In the full spectrum of ACS, the role of biomark-
ers for actionable risk stratification has proved useful in 
patients with unstable angina or non-STEMI. As PPCI is 
the cornerstone of STEMI treatment, the main interest 
of such biomarkers in this population, lies in their abil-
ity to provide long-term prognostication (focusing on 
the population of hospital survivors). Remarkably, we 
found superior predictive ability for Stanniocalcin-2 and 
IGFBP-4 in comparison to previous validated biomark-
ers such as high-sensitivity cardiac troponin, which may 
no longer provide added value in STEMI risk-assess-
ment [34]. It is possible that in the era of routine PPCI 
with subsequent decrease in infarct size, novel biomark-
ers representing different and specific pathways may 
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emerge as useful risk stratification tools. Our findings 
support the hypothesis that the Stanniocalcin-2/PAPP-
A/IGFBP-4 axis is of remarkable importance in the vas-
cular response to injury and in atherosclerosis and plays 
an important role in the risk stratification of STEMI 
patients. Accordingly, Stanniocalcin-2 and IGFBP-4 may 
become useful prognostic biomarkers for increased risk 
of adverse outcomes in STEMI patients; indeed, their 
prognostic value is additive to other traditional clinical 
risk factors in refining clinical decision making.
Limitations
Some limitations of our study should be acknowledged 
to aid in data interpretation. This is a single centre, pro-
spective study design, and the results must be interpreted 
in that light. Samples were collected at baseline with no 
measurement beyond; therefore, we are not able to evalu-
ate dynamic changes in variables over time. The cause 
of death for patients in the study was not investigated. 
Despite these limitations, our findings were representa-
tive of a broad range of unselected patients with STEMI, 
which reflect a real-life clinical scenario in our daily 
practice.
Conclusions
In contemporary-treated STEMI patients, Stanniocal-
cin-2 and IGFBP-4 were strong predictors of mortality 
and HF readmission and may become valuable cardio-
vascular biomarkers, combined with traditional clinical 
predictors, for identifying high-risk STEMI patients. The 
Stanniocalcin-2/PAPP-A/IGFBP-4 axis is a new disease 
pathway with a significant role in the risk stratification of 
STEMI patients. Further research is needed to validate 
our data.
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